Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.41 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4410497 | 0.91 | MAPK14 (0.44) | MAPK14MAPK11MAPK13MAPK12CSNK1D | |
| SCHEMBL4410550 | 0.85 | ALOX5 (0.49) | MAPK14MAPK11MAPK13MAPK12ALOX5 | |
| SCHEMBL4411060 | 0.82 | MAPK14 (0.44) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL4408770 | 0.80 | MAPK14 (0.46) | MAPK14MAPK11MAPK13MAPK12CSNK1D | |
| SCHEMBL4415373 | 0.79 | MAPK14 (0.44) | MAPK14MAPK11MAPK13MAPK12CSNK1D | |
| SCHEMBL4410172 | 0.78 | MAPK14 (0.47) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL4408284 | 0.74 | MAPK14 (0.58) | MAPK14MAPK11MAPK13MAPK12CSNK1D | |
| SCHEMBL4408115 | 0.73 | MAPK14 (0.47) | MAPK14MAPK11MAPK13MAPK12CSNK1D | |
| SCHEMBL4410204 | 0.72 | MAPK14 (0.46) | MAPK14MAPK11MAPK13MAPK12CSNK1D | |
| SCHEMBL4409114 | 0.70 | HTR3A (0.47) | MAPK14MAPK11MAPK13MAPK12ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264446-A9 | Condensed Pyridines as Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2009-10-22 | — | — | US | claimed |
| US-20080318977-A1 | Condensed Pyridines as Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2008-12-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264446-A9 | Condensed Pyridines as Kinase Inhibitors | MAPK1, MAP4K2, MAP3K1 | MAPK14 36/4885MAPK11 42/4885MAPK13 39/4885 |
| US-20080318977-A1 | Condensed Pyridines as Kinase Inhibitors | MAPK1, MAP4K2, MAP3K1 | MAPK14 36/4885MAPK11 42/4885MAPK13 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.